Resistance to different stages of androgen blockers leads to increased malignancy and heterogeneity of prostate cancer [4, 5], such as the trans-differentiation of classical prostate carcinoma to neuroendocrine prostate cancer (NEPC) [6, 7] and AR-negative prostate cancer [8]. Here, AR is linked to prostate carcinoma.